Clinical Trial Update: 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 study of 2-methoxyestradiol in patients with refractory or stage III multiple myeloma and other advanced solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Solid Tumors

Drugs mentioned

• 2-Methoxyestradiol (2-methoxyestradiol)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Refractory Multiple Myeloma, Stage III Multiple Myeloma | Phase 1 | Status: COMPLETED